Literature DB >> 2290447

Mode of action of the schistosomicide hycanthone: site of DNA alkylation.

S Archer1, W el-Hamouly, A Seyed-Mozaffari, R H Butler, L Pica-Mattoccia, D Cioli.   

Abstract

Condensation of hycanthone N-methylcarbamate (HNMC) with deoxyguanosine (dG) furnished a mixture of the N-1 and N2 adducts which were purified and characterized as their acetates. Condensation of HNMC with thymidine (T) gave the N-3 adduct in poor yield. Adenosine (A) and cytidine (C) did not react with HNMC. Incubation of schistosomes with either [3H]hycanthone (HC) or [3H]HNMC furnished DNA to which [3H]HC was covalently bound. The alkylated DNA was degraded enzymically and the radiolabeled nucleosides were separated using HPLC. Two major peaks were observed which coincided in retention time with the synthetic N-1 and N2 alkylated dG. Alkylated T was absent. Thus, the site of alkylation of DNA by either HC or HNMC is dG.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2290447     DOI: 10.1016/0166-6851(90)90133-7

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  3 in total

Review 1.  The redox biology of schistosome parasites and applications for drug development.

Authors:  Hsin-Hung Huang; Coraline Rigouin; David L Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Characterization of a programmed alteration in an 18S ribosomal gene that accompanies the experimental induction of drug resistance in Schistosoma mansoni.

Authors:  P J Brindley; S Heath; A P Waters; T F McCutchan; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

3.  Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies.

Authors:  Priscila H Goncalves; Francine High; Paul Juniewicz; Gareth Shackleton; Jing Li; Scott Boerner; Patricia M LoRusso
Journal:  Invest New Drugs       Date:  2008-05-01       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.